Swedbank AB Lowers Stock Holdings in Savara Inc. $SVRA

Swedbank AB lowered its position in shares of Savara Inc. (NASDAQ:SVRA) by 17.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 700,000 shares of the company’s stock after selling 150,000 shares during the period. Swedbank AB’s holdings in Savara were worth $3,822,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Prudential Financial Inc. bought a new position in shares of Savara during the 2nd quarter valued at about $30,000. BNP Paribas Financial Markets boosted its stake in Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after buying an additional 4,626 shares in the last quarter. Brevan Howard Capital Management LP purchased a new stake in Savara in the second quarter worth approximately $33,000. Russell Investments Group Ltd. grew its position in Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after acquiring an additional 9,463 shares during the last quarter. Finally, CIBC Bancorp USA Inc. bought a new position in Savara during the third quarter valued at approximately $44,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Trading Down 4.1%

Shares of NASDAQ:SVRA traded down $0.26 during trading on Friday, reaching $6.03. 1,720,421 shares of the company traded hands, compared to its average volume of 1,926,778. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. Savara Inc. has a 52-week low of $2.24 and a 52-week high of $7.01. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -10.77 and a beta of 0.24. The business’s fifty day moving average is $5.44 and its 200-day moving average is $5.56.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). As a group, analysts forecast that Savara Inc. will post -0.57 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SVRA. Oppenheimer assumed coverage on shares of Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating on shares of Savara in a report on Monday, March 16th. William Blair set a $10.00 price target on shares of Savara in a research note on Monday, March 16th. Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $10.14.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.